Press Release

Automation in Biopharma Industry Market to grow with a CAGR of 5.80%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Automation in Biopharma Industry Market.

 

According to TechSci Research report, “Global Automation in Biopharma Industry Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Automation in Biopharma Industry Market has valued at USD 1775.20 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.80% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. Data-driven decision-making is a significant driver of the demand for automation in the Global Automation in Biopharma Industry Market. The biopharma industry generates massive amounts of data during research, development, and manufacturing processes. Automation systems are essential for handling and managing this vast volume of data efficiently. Data in biopharma often involves intricate biological, chemical, and process information. Automation facilitates complex data analysis, making it easier for researchers and decision-makers to extract meaningful insights from the data. Automation technology allows for real-time monitoring of various bioprocesses. This real-time data provides immediate feedback, enabling timely decision-making and adjustments to ensure product quality and process optimization. Data-driven decision-making relies on predictive modeling to anticipate outcomes and optimize processes. Automation systems can be integrated with machine learning and artificial intelligence algorithms to develop predictive models based on historical data.

Data-driven analysis allows biopharma companies to identify potential risks early and take preventive measures. Automation systems provide the data needed to assess and mitigate risks effectively. Automation systems collect data over time, enabling continuous process improvement. Data-driven decision-making informs strategies for enhancing efficiency, product quality, and cost-effectiveness.

In the biopharma industry, automation entails the application of cutting-edge technologies and software to mechanize a range of activities in both biopharmaceutical manufacturing and research. This encompasses the automation of laboratory procedures, manufacturing processes, quality assessment, and data interpretation. The primary objective of automation in the biopharma industry is to enhance operational efficiency, accelerate processes, and enhance precision while concurrently decreasing errors and reducing the need for extensive human involvement. This automation may encompass the utilization of robotics, sensors, artificial intelligence, and other advanced technologies to optimize production procedures and elevate productivity.

In February 2023, Siemens Healthineers, a prominent medical technology company, and Unilabs, a leading provider of diagnostic services, have jointly announced a multi-year agreement with a value exceeding €200 million. Unilabs is making a substantial investment in Siemens Healthineers' cutting-edge technology, acquiring more than 400 laboratory analyzers to further enhance and upgrade its laboratory infrastructure. This strategic move is aimed at delivering an exceptional level of service to its customers. Within the framework of this agreement, Unilabs will continue its ongoing efforts to modernize its healthcare infrastructure across its network, with a primary focus on enhancing customer service and quality, ultimately leading to improved patient healthcare outcomes. The solutions provided by Siemens Healthineers will play a pivotal role in elevating Unilabs' laboratory operations, improving throughput, and ensuring clinical excellence throughout its testing network.

Ethical concerns in the Global Automation in Biopharma Industry Market can be a significant challenge, particularly in the context of research, development, and manufacturing of biopharmaceutical products. Automation systems in the biopharma industry often handle sensitive patient data and intellectual property. Ensuring the privacy and security of this data is a critical ethical concern. Breaches or unauthorized access to patient information or proprietary research can have serious consequences. In the context of personalized medicine and clinical trials, ethical considerations include obtaining informed and voluntary consent from patients whose data and samples are being used in research. Ensuring that patients understand the implications of their participation is essential. Biopharmaceutical companies must be transparent about the use of automation technology and how it impacts research and manufacturing processes. Ethical concerns arise when patients or researchers are not fully informed about the use of automation or its potential implications. The use of automation can lead to increased costs in drug development and manufacturing. Ethical concerns revolve around ensuring that lifesaving or life-improving therapies remain accessible and affordable to all patients, rather than being prohibitively expensive.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Automation in Biopharma Industry Market.”

 

Global Automation in Biopharma Industry Market is segmented based on Technology, Application, Component, and by region.  Based on the Technology, Global Automation in Biopharma Industry Market is segmented into Automation Technology, Digitization Technology. Automation technology in the biopharmaceutical (biopharma) industry encompasses a wide range of innovative tools and systems designed to streamline and enhance various processes across research, development, and manufacturing. These technologies play a crucial role in improving efficiency, data quality, and the overall production of biopharmaceutical products. Laboratory automation technology includes robotic systems, liquid-handling platforms, and sophisticated software that enable precise and high-throughput processing of samples. Automated liquid handlers, for example, can accurately dispense reagents and samples in various assays, speeding up experiments and minimizing human errors. Automation technology is used in biopharmaceutical manufacturing to control and monitor critical process parameters. This includes automated systems for managing cell culture, fermentation, purification, and other manufacturing steps. These systems ensure consistent product quality and reduce the risk of variations.

Based on Region, North America held the largest share in the Global Automation in Biopharma Industry Market. North America has a well-educated and skilled workforce in the fields of biopharmaceuticals, engineering, and automation, which supports the implementation and maintenance of automation systems. The region has a large and growing market for biopharmaceutical products, including drugs and therapies, which drives the need for automation to meet increasing production demands efficiently. North American companies and research institutions are at the forefront of biopharmaceutical research and development. Automation is crucial in accelerating drug discovery and development processes. The region fosters collaboration between academia, government agencies, and the private sector. This collaborative ecosystem facilitates knowledge sharing and technology adoption. Strong intellectual property protection in North America encourages companies to invest in automation as a means of protecting their proprietary processes and innovations.

 

Some of the major companies operating in the Global Automation in Biopharma Industry Market include:

  • PerkinElmer, Inc.
  • AMETEK, Inc.
  • Autodesk, Inc.
  • Baumueller-Nuermont Corp
  • Emerson Electric Co.
  • Kawasaki Robotics
  • RheoSense Inc.
  • Rockwell Automation, Inc.
  • Sartorius Stedim Biotech SA
  • Siemens Healthineers

 

Download Free Sample Report

Customers can also request 10% free customization on this report.

 

“Certain areas, particularly in North America, are projected to exert significant demand for Automation in Biopharma Industry. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Automation in Biopharma Industry Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Automation in Biopharma Industry Market by Technology (Automation Technology, Digitization Technology), By Application (Clinical Phase, Drug Discovery Phase, Production Phase), by Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Automation in Biopharma Industry Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Automation in Biopharma Industry Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News